Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial
Source Human Gene Therapy 2003;14:1347–1360
Authors Di Nicola,M.; Carlo-Stella,C.; Anichini,A.; Mortarini,R.; Guidetti,A.; Tragni,G.; Gallino,F.; Del Vecchio,M.; Ravagnani,F.; Morelli,D.; Chaplin,P.; Arndtz,N.; Sutter,G.; Drexler,I.; Parmiani,G.; Cascinelli,N.; Gianni,A.M.;
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. Bavarian Nordic Research Institute, Munich, Germany. Institute for Molecular Virology, GSF—National Research Center, Munich, Germany.
